samedan logo
 
 
spacer
home > ict > summer 2018 > restricting remedies
PUBLICATIONS
International Clinical Trials

Restricting Remedies

Herbal medicine has been practised in many countries for centuries. The 2004 European Traditional Herbal Medicinal Products Directive took full effect in the UK in 2011. This legislation effectively banned the importation and sale of large-scale manufactured herbal medicine products and severely limited the scope of some herbal practitioners to continue practising. At present, under UK law, a herbal practitioner is permitted to see individual patients, offer diagnoses, and prepare herbal treatments on their own premises, as long as these preparations do not contain banned or restricted substances. Thus, where ‘herbal’ products derived from the cannabis plant are concerned because they are banned or restricted substances, they cannot be prescribed by herbal practitioners. Herein lies the problem of the use of cannabis oil for the treatment of rare forms of childhood epilepsy, which has gripped the media of late.

In a review into cannabis-related medicinal products, the UK’s Chief Medical Officer and Advisor, Professor Dame Sally Davies, has concluded that evidence shows the therapeutic benefit of cannabis-based medicines for some conditions. The finding has prompted Home Secretary Sajid Javid to commission the second part of the UK’s review into cannabisrelated medicinal products, led by an independent advisory committee. However, prior to this review, cannabis oil had been prescribed to a young boy with epilepsy on the NHS. Reports have called this the “first case of its kind” in the UK.

Cannabis oil is a medicine containing a part of the cannabis plant called cannabidiol (CBD). It does not contain the ‘psychoactive’ part of cannabis – the part that causes the feeling of being high. Last year, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) classed CBD as a medicine in the UK and not a herbal. The agency has thus said that CBD products are required to be licensed, meaning they “have to meet safety, quality and efficacy standards,” as would be the case for any therapeutic drug prescribed in the UK.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer

Print this page
Send to a friend
Privacy statement
News and Press Releases

Temperature Controlled Logistics returns with a top schedule for 2019

The 18th annual Temperature Controlled Logistics Conference will bring together supply chain, logistics and quality experts from around the globe to experience four days of ‘unmissable’ workshops, case studies, panels, interactive discussion groups and technology showcases.
More info >>

White Papers

The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing

GE Healthcare Life Sciences

For the past several years, the biopharma industry has been buffeted by dynamic market conditions that are rapidly reshaping manufacturing requirements. These factors include: • The rise of small-market pharmaceuticals that do not require the production scale of the previous “blockbuster” drug model • Increased titers and process productivity that generate more bulk-product within a much smaller manufacturing footprint • The emergence of biosimilars and continued evolution of healthcare reform, which will increasingly pressure drug pricing and require greater cost discipline • Greater competition and shorter patent protection timelines, which will further ratchet up time-to-market pressures • Tighter capital markets that will create heightened scrutiny for all new investment projects
More info >>

 
Industry Events

Drug Delivery Partnerships 2019

28-30 January 2019, PGA National Resort & Spa in Palm Beach Gardens, FL

For 23 years, DDP has been the world’s largest drug delivery meeting place to accelerate drugs to market and lengthen lifecycles for long term profitability by finding new partners, new drug delivery technologies, and new formulation development strategies. Year after year this event brings together top scientists and business development leaders from Biotech, Pharma, Generics, Specialty Pharma and Drug Delivery companies to share, discuss, and collaborate. If you work in drug delivery, commercialization/licensing, med device, formulation, biologics, biosimilars, and similar areas, you can’t miss this event!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement